Advertisement
Screener

BRISTOL-MYERS SQUIBB COMPANY (BMY) Overview

BRISTOL-MYERS SQUIBB COMPANY (BMY) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual 1.62; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual 1.31; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual 1.08; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual 0.64; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$43.50$48.37$53.78$59.79$66.48$73.912025-11-062026-11-06$37.68$44.63$52.86$62.61$74.15$87.832021-11-082026-11-06$37.68$45.97$56.10$68.45$83.52$101.922016-11-072026-11-06$16.40$25.58$39.91$62.27$97.14$151.562006-11-062026-11-06$0.89$3.14$11.03$38.77$136.27$478.951972-06-012026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$62.14
Previous close
$62.86
Change
-$0.72
Change (%)
-1.15%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

BMY
+20.50%
S&P 500
(m)

1 year

BMY
+49.25%
S&P 500
(m)

3 years

BMY
+24.75%
S&P 500
(m)

5 years

BMY
+27.29%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual 1.62

0.560.871.181.491.8031 Mar 2025: estimate (m); actual 1.2031 Mar 2025(m)30 Jun 2025: estimate (m); actual 0.6430 Jun 2025(m)30 Sept 2025: estimate (m); actual 1.0830 Sept 2025(m)31 Mar 2026: estimate (m); actual 1.3131 Mar 2026(m)30 Jun 2026: estimate (m); actual 1.6230 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)1.62(m)(m)
1 Jan 202631 Mar 2026(m)1.31(m)(m)
1 Jul 202530 Sept 2025(m)1.08(m)(m)
1 Apr 202530 Jun 2025(m)0.64(m)(m)
1 Jan 202531 Mar 2025(m)1.20(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual 3.46

-4.49-2.36-0.221.914.0431 Dec 2021: estimate (m); actual 3.1231 Dec 2021(m)31 Dec 2022: estimate (m); actual 2.9531 Dec 2022(m)31 Dec 2023: estimate (m); actual 3.8631 Dec 2023(m)31 Dec 2024: estimate (m); actual -4.4131 Dec 2024(m)31 Dec 2025: estimate (m); actual 3.4631 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)3.46(m)(m)
1 Jan 202431 Dec 2024(m)-4.41(m)(m)
1 Jan 202331 Dec 2023(m)3.86(m)(m)
1 Jan 202231 Dec 2022(m)2.95(m)(m)
1 Jan 202131 Dec 2021(m)3.12(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 12.97B ■ Earnings 3.32B — Profit margin 25.57%

-1.56B7.7%3.81B14.0%9.17B20.3%14.53B26.6%30 Sept 2025: revenue 12.22B; earnings 2.20B; profit margin 18.01%30 Sept 202531 Dec 2025: revenue 12.50B*; earnings 1.09B*; profit margin 8.69%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 11.49B; earnings 2.68B; profit margin 23.30%31 Mar 202630 Jun 2026: revenue 12.97B; earnings 3.32B; profit margin 25.57%30 Jun 2026

31 Dec 2025 ■ Revenue 48.19B ■ Earnings 7.05B — Profit margin 14.64%

-15.82B-19.5%7.84B-6.7%31.51B6.0%55.17B18.8%31 Dec 2022: revenue 46.16B; earnings 6.33B; profit margin 13.71%31 Dec 202231 Dec 2023: revenue 45.01B; earnings 8.03B; profit margin 17.83%31 Dec 202331 Dec 2024: revenue 48.30B; earnings -8.95B; profit margin -18.53%31 Dec 202431 Dec 2025: revenue 48.19B; earnings 7.05B; profit margin 14.64%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$62.14(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$62.14High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning BMY

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending (m).

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
(m)
Profit margin
(m)
Return on assets · 12 month
(m)
Stock compensation expense · all employees · 12 months
(m)
Index membership
(m)
Employees
32.50K
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
11.21M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
0.99%*
Total return · month
-5.58%*
Total return · quarter
8.58%*
Total return · half year
9.74%*
Total return · year to date
20.50%*
Total return · 1 year
49.25%*
Total return · 3 years
24.75%*
Total return · 5 years
27.29%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
(m)
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

BRISTOL-MYERS SQUIBB COMPANY Overview

View more →

(m)

(m)

SEC CIK
14272
Industry (SIC)
2834 Pharmaceutical Preparations
Country of operation
United States
Business address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, New Jersey, 08543, United States
Fiscal year end
1231
Phone
6092524621

Similar stocks

Stock NameCountryMarket CapPE Ratio
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
PFIZER INC (PFE)United States$162.042B31.94
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64